Science Sun Pharm: Net profit in the third quarter was 4.0733 million yuan, a decrease of 41.41%Zhitong·Oct 23, 2025 at 07:23 AM300485+3.29%
Science Sun Pharm shareholders Ma Li and Liu Shuqin plan to collectively reduce their holdings by no more than 2%Zhitong·Sep 19, 2025 at 06:57 AM300485+3.29%
Science Sun Pharm: In the first half of 2025, net profit was 47.7862 million yuan, a year-on-year increase of 145.45%Zhitong·Aug 21, 2025 at 03:19 AM300485+3.29%
China Science Sun Pharm is in talks to authorize weight loss drugs in the United States. (Reuters)Wallstreetcn·Jul 25, 2025 at 02:54 AM300485+3.29%
The monoclonal antibody concept was active at the beginning of the trading session, with Science Sun Pharm and HAINAN HAIYAO both rising over 9%, while YILING PHARMACEUTICAL, Zhongyuan Union, and FUDANZHANGJIANG also saw gainsZhitong·Jul 7, 2025 at 08:36 PM688505+1.96%01349+1.26%
Innovative drug concept stocks are repeatedly active, Thalys has three consecutive limit-upsZhitong·Jul 2, 2025 at 08:42 PM300485+3.29%603716+3.38%
The biopharmaceutical sector continues to adjust, with *ST Four Rings hitting the daily limit down, Rongchang Bio falling over 18%, and Mabwell, SDKX, Science Sun Pharm, OPM, Aidea Pharma, and others following suitZhitong·Jun 26, 2025 at 01:17 AM688293-2.72%688488+2.22%
"Shanghai and Shenzhen" bank stocks support the Shanghai Composite Index to stabilize slightly in the first half of the day, while oil and gold stocks are weak, and innovative drug concept stocks riseAASTOCKS·Jun 19, 2025 at 10:30 PM601398-1.96%01398-1.70%
Science Sun Pharm signed a transfer contract with BGI Protein regarding the NeoAB33 new drug project related technologyZhitong·Jun 19, 2025 at 05:05 AM300485+3.29%
Science Sun Pharm released its first-quarter performance, with a net profit attributable to the parent company of 39.97 million yuanZhitong·Apr 23, 2025 at 03:32 AM300485+3.29%
Pharmaceutical stocks are repeatedly active, MEDISAN and Rundu Pharma hit the limit upZhitong·Apr 2, 2025 at 08:40 PM300485+3.29%002900-0.87%
Science Sun Pharm released its 2024 annual performance, turning from profit to a loss of 68.8531 million yuanZhitong·Mar 28, 2025 at 03:42 AM300485+3.29%
Science Sun Pharm: Passed the drug GMP compliance inspectionZhitong·Mar 28, 2025 at 03:35 AM300485+3.29%
Science Sun Pharm's subsidiary has received the clinical trial approval notice for the drugZhitong·Mar 17, 2025 at 03:09 AM300485+3.29%
Science Sun Pharm issues a profit warning, expecting a net loss of RMB 59.1728 million to RMB 88.7592 million for the fiscal year 2024Zhitong·Jan 24, 2025 at 02:33 AM300485+3.29%
